Inflammatory Bowel Disease (IBD) Flashcards
Clinical Remission
- Patient is asymptomatic
- Can occur on its own, or with medical intervention
Mild IBD
- Patient is ambulatory
- Tolerating oral diet
- < 10% loss in weight
- No symptoms of systemic disease
- No blood in stool
Moderate to Sever IBD
- Failed treatment
- Symptoms of systemic fever
- Stools may be bloody (> 4 times/day)
Severe to Fulminant IBD
- Persistent symptoms despite steroid or biologic
- In hospital with high fever
- Blood in stools (> 6 times/day)
Drugs to avoid in IBD
- Antidiarrheal meds (Loperamide, atropine, codeine, diphenoxylate)
- NSAIDs: can worsen GI symptoms
- Opioids: reduce GI motility
Non-pharmacological treatment of IBD
- High fiber diet
- Routine physical activity
Treatment Mild to Moderate IBD
-Oral sulfasalazine (4-6g/day)
or Oral mesalamine (3-4g/day)
a) Ulcerative Colitis (UC)-Distal disease; use mesalamine, enema, or suppository
or corticosteroid suppository
b) Crohn’s Disease (CD)-If only in the small bowel or perianal disease Metronidazole (Flagyl) 10 to 20mg/kg/day
Treatment for Moderate to Severe IBD
- Oral sulfasalazine or mesalamine PLUS prednisone (40-60mg/day)
a) UC Inadequate response: add azathioprine, mercaptopurine or infliximab
b) CD Refactory and fistulizing disease: add infliximab - If inadequate response; add adalimumab, natalizumab, or certolizumab
Treatment for Severe to Fulminant IBD
- IV hydrocortisone 100mg q6-8h
- If no response in 7 days; use IV cyclosporine 4mg/kg/day
Remission in Mild to Moderate IBD
- Keep the same medications, but reduce the dose by 50%
- If enema or suppository used; reduce dosing frequency
Remission in Moderate to Severe IBD
- Taper prednisone
- Then reduce sulfasalazine or mesalamine after 1-2 months to 50% of the original dose
Remission in Fulminant IBD
- Change IV hydrocortisone to oral prednisone
- Add sulfasalazine or mesalamine
- Steroid should be withdrawn after 1-2 months and remission maintained with sulfasalazine
Sulfasalazine
- Unclear anti-inflammatory effects
- Contraindicated in patients with a sulfa allergy
Mesalamine
- Unclear anti-inflammatory effects
- “ghost” tablet may be found in patient’s stool
Azathioprine and Mercaptopurine
- Main concern is chronic immunosuppression
- Patients with TPMY deficiency are at increased risk of myelosuppression and may need lower doses
- Can cause sever nausea, vomiting, diarrhea, rash, increase in AST/ALT